Outcome in children with purpura fulminans: report on 16 patients

Aytemiz Gürgey1, Selin Aytac, Guler Kanra

  • 1Hacettepe University, Faculty of Medicine, Department of Pediatrics, Ankara, Turkey. agurgey@hacettepe.edu.tr

Insights

Purpura fulminans (PF) in young children is linked to severe infections, factor V G1691A mutation, and congenital heart disease, often requiring amputation. Early treatment improves survival rates, suggesting PF may not be a lethal disease.

Area of Science:

  • Pediatrics
  • Hematology
  • Infectious Diseases

Background:

  • Purpura fulminans (PF) is a severe, acute condition with high mortality, often linked to infections in children.
  • Other underlying conditions may also contribute to PF development.

Purpose of the Study:

  • To investigate underlying disorders and associated conditions in pediatric PF.
  • To analyze the outcomes and risk factors for PF in children.

Main Methods:

  • Retrospective analysis of 16 children (3.5 months to 12 years) diagnosed with PF.
  • Evaluation of associated conditions, genetic mutations (Factor V G1691A), protein C/S deficiencies, and treatment outcomes.
  • Assessment of amputation rates and survival.

Main Results:

  • Children aged 4 years or younger (81%) were predominantly affected.
  • Factor V G1691A mutation (46%) and protein deficiencies (Protein C: 37.5%, Protein S: 56%) were common.
  • Amputation was required in 69% of younger children and 33% of older children, particularly those with Factor V mutation and severe infections.

Conclusions:

  • Age under 4, Factor V G1691A mutation, and congenital heart disease are risk factors for PF in severe infections.
  • The study suggests PF is treatable with improved survival rates, challenging its previously lethal perception.
  • Changes in the etiological profile of PF may be influenced by immunization and healthcare advancements.